Department of Surgery, Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy.
Department of Surgery, Koç University School of Medicine, Istanbul, Turkey.
Br J Surg. 2024 Aug 2;111(8). doi: 10.1093/bjs/znae181.
Laparoscopic liver surgery is increasingly used for more challenging procedures. The aim of this study was to assess the feasibility and oncological safety of laparoscopic right hepatectomy for colorectal liver metastases after portal vein embolization.
This was an international retrospective multicentre study of patients with colorectal liver metastases who underwent open or laparoscopic right and extended right hepatectomy after portal vein embolization between 2004 and 2020. The perioperative and oncological outcomes for patients who underwent laparoscopic and open approaches were compared using propensity score matching.
Of 338 patients, 84 patients underwent a laparoscopic procedure and 254 patients underwent an open procedure. Patients in the laparoscopic group less often underwent extended right hepatectomy (18% versus 34.6% (P = 0.004)), procedures in the setting of a two-stage hepatectomy (42% versus 65% (P < 0.001)), and major concurrent procedures (4% versus 16.1% (P = 0.003)). After propensity score matching, 78 patients remained in each group. The laparoscopic approach was associated with longer operating and Pringle times (330 versus 258.5 min (P < 0.001) and 65 versus 30 min (P = 0.001) respectively) and a shorter length of stay (7 versus 8 days (P = 0.011)). The R0 resection rate was not different (71% for the laparoscopic approach versus 60% for the open approach (P = 0.230)). The median disease-free survival was 12 (95% c.i. 10 to 20) months for the laparoscopic approach versus 20 (95% c.i. 13 to 31) months for the open approach (P = 0.145). The median overall survival was 28 (95% c.i. 22 to 48) months for the laparoscopic approach versus 42 (95% c.i. 35 to 52) months for the open approach (P = 0.614).
The advantages of a laparoscopic over an open approach for (extended) right hepatectomy for colorectal liver metastases after portal vein embolization are limited.
腹腔镜肝切除术越来越多地用于更具挑战性的手术。本研究旨在评估门静脉栓塞后行腹腔镜右半肝切除术治疗结直肠癌肝转移的可行性和肿瘤安全性。
这是一项国际回顾性多中心研究,纳入了 2004 年至 2020 年间接受门静脉栓塞后行开腹或腹腔镜右半肝及扩大右半肝切除术的结直肠癌肝转移患者。采用倾向评分匹配比较腹腔镜和开腹手术患者的围手术期和肿瘤学结果。
338 例患者中,84 例行腹腔镜手术,254 例行开腹手术。腹腔镜组患者较少行扩大右半肝切除术(18%对 34.6%(P=0.004))、两阶段肝切除术(42%对 65%(P<0.001))和主要合并手术(4%对 16.1%(P=0.003))。行倾向评分匹配后,每组各有 78 例患者。与开腹手术相比,腹腔镜手术的手术时间和阻断时间较长(330 分钟比 258.5 分钟(P<0.001)和 65 分钟比 30 分钟(P=0.001)),住院时间较短(7 天比 8 天(P=0.011))。R0 切除率无差异(腹腔镜组为 71%,开腹组为 60%(P=0.230))。腹腔镜组的无疾病生存中位时间为 12(95%可信区间 10 至 20)个月,开腹组为 20(95%可信区间 13 至 31)个月(P=0.145)。腹腔镜组的总生存中位时间为 28(95%可信区间 22 至 48)个月,开腹组为 42(95%可信区间 35 至 52)个月(P=0.614)。
对于门静脉栓塞后行结直肠癌肝转移的(扩大)右半肝切除术,腹腔镜相对于开腹手术的优势有限。